Articolul precedent |
Articolul urmator |
339 1 |
Ultima descărcare din IBN: 2021-04-06 12:17 |
SM ISO690:2012 LEAHU, Pavel. Abordarea neuromodulatorie a patologiei neurologice paroxismale. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 362. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 362-362 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Nowadays, modern neuromodulatory approach offers a vast range of devices and techniques in the treatment of neurological patients suffering from paroxysmal disorders such as epilepsy and migraine. Among non-pharmacologic therapies TMS has been broadly studied in these patients showing good results. Objective of the study. To asses the safety and efficacy of high frequency transcranial magnetic stimulation in the prevention of migraine attacks. Material and Methods. A longitudinal, double-blinded, rTMS-intervention study with patients with episodic migraine (with and without aura, 2-14 attacks per month) had been performed. After a baseline follow up for 1 month, subjects had 6 sessions of rTMS during 2 weeks and received multifocal rTMS or sham stimulation, with a future 3 months assessment by specific neurological questionnaires and frequency of headache Results. After stimulation, the real rTMS (treatment) group showed a reduction in the number of attacks – 7.5 ± 3.7 at baseline to 3.8 ± 2.7 attacks at 3 months period (p<0.05). The effect lasting at least three months. The number of attacks was also reduced in the placebo group (7.3 ± 3.6 to 4.4 ± 2.9) (p>0.05). There was a significant reduction in the intensity of attacks at 4 weeks after the treatment in the treatment group (6.7 ± 1.5 at baseline; 5.3 ± 2.5 at 4 weeks (p<0.05). The conducted questionnaires revealed a positive impact on quality of life and functional outcome. There were no serious adverse events reported. Conclusion. Our study showed evidence that the studied rTMS protocol significantly reduced the frequency and intensity of migraine attacks compared to placebo treatment with no serious adverse events. Non-invasive neuro-modulatory techniques such as rTMS had shown promising results. |
||||||
Cuvinte-cheie Transcranial, Magnetic, stimulation, multifocal, migraine, stimulare, magnetică, transcraniană, multifocală, migrena |
||||||
|